Portfolio company Utility Therapeutics was acquired by Alembic Pharmaceuticals following FDA approval of its lead antibiotic PIVYA.
Utility Therapeutics is a developer of antibiotics aimed at treating urinary tract infections and multi-drug resistant infections, known for its product Pivmecillinam
Utility Therapeutics is a developer of antibiotics aimed at treating urinary tract infections and multi-drug resistant infections, known for its product Pivmecillinam.